Related references
Note: Only part of the references are listed.Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome
Eduardo Molina-Jijon et al.
KIDNEY INTERNATIONAL (2020)
Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome
Bernhard N. Bohnert et al.
ACTA PHYSIOLOGICA (2019)
Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome
Bernhard N. Bohnert et al.
KIDNEY INTERNATIONAL (2018)
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
Yuki Awanami et al.
BMC NEPHROLOGY (2017)
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia
Mary E. Haas et al.
CIRCULATION (2016)
Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences
Nosratola D. Vaziri
KIDNEY INTERNATIONAL (2016)
Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Vikas Sharotri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Share Paper
